P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?

Mathurin Fumery (1, 2) , S. Nancey (3, 4, 5) , J. Filippi , R. Altwegg (6) , X. Hebuterne (7) , G. Boschetti (4, 3, 5) , P. Veyrard , Clara Yzet (1, 8) , S. Paul (9) , X. Roblin (9)

1 CHU Amiens-Picardie
2 PERITOX - Périnatalité et Risques Toxiques - UMR INERIS_I 1
3 CHLS - Centre Hospitalier Lyon Sud [CHU - HCL]
4 HCL - Hospices Civils de Lyon
5 CIRI - Centre International de Recherche en Infectiologie - UMR
6 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
7 Département de Gastroentérologie
8 SSPC - Simplification des soins chez les patients complexes - UR UPJV 7518
9 CHU de Saint-Etienne - Centre Hospitalier Universitaire de Saint-Etienne

Domaines: Sciences du Vivant [q-bio]

Mathurin Fumery, S. Nancey, J. Filippi, R. Altwegg, X. Hebuterne, et al.. P465 Is golimumab serum level predictive of clinical remission after intensification for loss of response in patients with ulcerative colitis?. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I439. ⟨hal-03665864⟩